Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
European Journal of Immunology
|
July 25, 2022
Regulatory T-cell development in the tumor microenvironment
Kota Itahashi, Takuma Irie, Hiroyoshi Nishikawa
Nature Reviews. Clinical Oncology
|
February 29, 2024
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine
Shogo Kumagai, Kota Itahashi, Hiroyoshi Nishikawa
Cancer Science
|
March 8, 2017
Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan
Shunsuke Kondo, Hiroko Hosoi, Kota Itahashi, et al.
Investigational New Drugs
|
August 8, 2018
Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015
Kota Itahashi, Toshio Shimizu, Takafumi Koyama, et al.
Journal of Thoracic Disease
|
June 11, 2019
Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with <i>EGFR</i>-mutated non-small cell lung cancer: a retrospective study
Kazushi Yoshida, Shintaro Kanda, Hideaki Shiraishi, et al.
Clinical Lung Cancer
|
January 10, 2017
Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis
Tetsuhiko Asao, Yutaka Fujiwara, Kota Itahashi, et al.
Cancer Science
|
June 9, 2016
Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
Yutaka Fujiwara, Akinobu Hamada, Hidenori Mizugaki, et al.
Frontiers in Medicine
|
November 27, 2018
Evaluating Clinical Genome Sequence Analysis by Watson for Genomics
Kota Itahashi, Shunsuke Kondo, Takashi Kubo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2021
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto, et al.
Cancer Immunology Research
|
November 27, 2024
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Ayaka Tsuge, Sho Watanabe, Akihito Kawazoe, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
European Journal of Immunology
|
July 25, 2022
Regulatory T-cell development in the tumor microenvironment
Kota Itahashi, Takuma Irie, Hiroyoshi Nishikawa
Nature Reviews. Clinical Oncology
|
February 29, 2024
Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine
Shogo Kumagai, Kota Itahashi, Hiroyoshi Nishikawa
Cancer Science
|
March 8, 2017
Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan
Shunsuke Kondo, Hiroko Hosoi, Kota Itahashi, et al.
Investigational New Drugs
|
August 8, 2018
Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991-2015
Kota Itahashi, Toshio Shimizu, Takafumi Koyama, et al.
Journal of Thoracic Disease
|
June 11, 2019
Difference in central nerve system metastasis during gefitinib or erlotinib therapy in patients with <i>EGFR</i>-mutated non-small cell lung cancer: a retrospective study
Kazushi Yoshida, Shintaro Kanda, Hideaki Shiraishi, et al.
Clinical Lung Cancer
|
January 10, 2017
Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis
Tetsuhiko Asao, Yutaka Fujiwara, Kota Itahashi, et al.
Cancer Science
|
June 9, 2016
Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB1 polymorphism
Yutaka Fujiwara, Akinobu Hamada, Hidenori Mizugaki, et al.
Frontiers in Medicine
|
November 27, 2018
Evaluating Clinical Genome Sequence Analysis by Watson for Genomics
Kota Itahashi, Shunsuke Kondo, Takashi Kubo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2021
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto, et al.
Cancer Immunology Research
|
November 27, 2024
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment
Ayaka Tsuge, Sho Watanabe, Akihito Kawazoe, et al.
Page
of 2